Grown Rogue International (GRUSF) Liabilities and Shareholders Equity (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Liabilities and Shareholders Equity of $65.8 million for Q1 2026, up 4.95% quarter-over-quarter from $62.7 million in Q4 2025.
Grown Rogue International (GRUSF) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Grown Rogue International's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $65.8 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $65.8 million; the TTM figure through Mar 2026 stood at $55902.6 billion (up 95657570.23% YoY), while the FY2025 annual figure was $62.7 million, changed N/A from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $65.8 million, up from $62.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $55902.5 billion in Q3 2025, with the low at $12.3 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $28.1 million (2024), against an average of $6211.4 billion.
- Peak annual rise in Liabilities and Shareholders Equity reached 184514363.33% in 2025, while the deepest fall reached 184514363.33% in 2025.
- Grown Rogue International's Liabilities and Shareholders Equity stood at $12.3 million in 2022, then jumped by 76.5% to $21.8 million in 2023, then jumped by 39.27% to $30.3 million in 2024, then surged by 107.07% to $62.7 million in 2025, then grew by 4.95% to $65.8 million in 2026.
- Business Quant data shows GRUSF's Liabilities and Shareholders Equity at $65.8 million in Q1 2026, $62.7 million in Q4 2025, and $55902.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Grown Rogue International | 110.47 Mn | 98.93 Mn | 5.37 Mn | 65.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.02 Mn |
| Mar 31, 2026 | 65.84 Mn |
| Dec 31, 2025 | 62.74 Mn |
| Sep 30, 2025 | 55,902.47 Bn |
| Sep 30, 2024 | 30.30 Mn |
| Jun 30, 2024 | 28.14 Mn |
| Dec 31, 2023 | 21.75 Mn |
| Jul 31, 2023 | 20.38 Mn |
| Jan 31, 2023 | 18.78 Mn |
| Oct 31, 2022 | 12.33 Mn |
| Apr 30, 2021 | 8.69 Mn |
| Jan 31, 2021 | 5.71 Mn |
| Oct 31, 2020 | 3.76 Mn |
| Jul 31, 2020 | 4.03 Mn |
| Apr 30, 2020 | 3.80 Mn |
| Jan 31, 2020 | 3.17 Mn |
| Oct 31, 2019 | 2.93 Mn |
| Jan 31, 2019 | 6.52 Mn |
| Oct 31, 2018 | 5.37 Mn |
| Aug 31, 2018 | 25,236.92 |